Evaluation of Checkpoint Inhibitors in Cancer Patients With End-stage Renal Disease on Hemodialysis: Case Series and Review of the Literature
Authors:
- 29 July 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 43 (8) , 244-249
Abstract
Checkpoint inhibitors (CPIs) have become standard of care for multiple types of malignancies and while end-stage renal disease is not a contraindication, these patients are frequently excluded from clinical trials. As a result, there is limited data regarding the safety and efficacy of CPI use in this patient population. In this case series, we report outcomes and adverse events in 8 patients on hemodialysis treated with CPIs. Treatment was overall well-tolerated with adverse events in 3 of 8 (37.5%) patients, with 1 (12.5%) having a grade 4 adverse event, which is comparable to the rate reported in literature for the overall population receiving CPI. No treatment related deaths were seen. Because of small sample size, efficacy data is limited. Further studies are needed in this patient population to elucidate the true incidence of adverse events and antitumor activity.Keywords
This publication has 29 references indexed in Scilit:
- Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on DialysisEuropean Urology, 2016
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaAnnals of Oncology, 2016
- Tumor Regression and Allograft Rejection after Administration of Anti–PD-1New England Journal of Medicine, 2016
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysisBMC Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2015
- Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal diseaseCancer Management and Research, 2015
- Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) studyAnnals of Oncology, 2012
- Screening, Diagnosis, and Treatment of Cancer in Long-Term Dialysis PatientsClinical Journal of the American Society of Nephrology, 2007
- Cancer in patients on dialysis for end-stage renal disease: an international collaborative studyThe Lancet, 1999